This study is designed to evaluate the safety and plasma concentrations of PF-06412562 in healthy volunteers following three times daily oral dosing of PF-06412562 for 14 days
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
40
oral dosing of 3 mg PF-06412562 tablets three times a day for 14 days
oral dosing of 10 mg PF-06412562 tablets three times a day for 14 days
oral dosing of 25 mg PF-06412562 tablets three times a day for 14 days
Pfizer Investigational Site
New Haven, Connecticut, United States
Safety and toleration assessed by: adverse events, supine and standing vital sign measurements, electrocardiogram (ECG) standard 12 lead, blood and urine safety laboratory tests ,CogState and C-SSRS.
Time frame: 0-15 days
Pharmacokinetics: Cmax, Tmax, AUCτ Ctrough, PTR, Rac on Cmax and AUCτ t1/2, CL/F, PTR,
Time frame: 0-15 days
CogState at followup
Time frame: 22-25 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
oral dosing of PF-06412562 tablets three times a day for 14 days. Dosage and frequency to-be-determined based on previous cohorts
oral dosing of PF-06412562 tablets three times a day for 14 days. Dosage and frequency to-be-determined based on previous cohorts